ethinylestradiol/desogestrel 0,03 mg/0,15 mg teva, tabletten
cyclessa desogestrel and ethinyl estradiol
organon usa inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.1 mg
ortho cept desogestrel and ethinyl estradiol
janssen pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg
kimidess- desogestrel and ethinyl estradiol kit
par pharmaceutical - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - kimidess® is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. table ii: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, united states. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year 3 adapted from hatcher et al., 1998, ref#1. 1 among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience
desogen desogestrel and ethinyl estradiol
organon usa inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg
azurette desogestrel/ethinyl estradiol and
watson pharma, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg
reclipsen desogestrel and ethinyl estradiol
actavis pharma, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3) - desogestrel 0.15 mg
cyred (desogestrel and ethinyl estradiol tablets usp, 0.15 mg/0.03 mg)
rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - cyred® (desogestrel and ethinyl estradiol tablets usp, 0.15 mg/0.03 mg) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typic
cerazette 75 µg tabl.
organon belgium bv-srl - desogestrel 0,075 mg - tablet - 75 µg - desogestrel 75 µg - desogestrel
desoceane 75 µg film-coat. tabl.
gedeon richter plc - desogestrel 0,075 mg - film-coated tablet - 75 µg - desogestrel 75 µg - desogestrel